Literature DB >> 15743845

Use of an intramedullary rod for the treatment of congenital pseudarthrosis of the tibia. Surgical technique.

Matthew B Dobbs1, Margaret M Rich, J Eric Gordon, Deborah A Szymanski, Perry L Schoenecker.   

Abstract

BACKGROUND: The treatment of congenital pseudarthrosis of the tibia remains difficult and controversial. The purpose of this study was to evaluate the long-term results of a technique consisting of excision of the pseudarthrosis, autologous bone-grafting, and insertion of a Williams intramedullary rod into the tibia.
METHODS: Twenty-one consecutive patients with congenital pseudarthrosis of the tibia were managed with this technique between 1978 and 1999, and the results were retrospectively reviewed. The mean age of the patients at the time of the latest follow-up was 17.2 years (range, seven to twenty-five years), and the mean duration of postoperative follow-up was 14.2 years (range, three to twenty years).
RESULTS: Initial consolidation occurred in eighteen of the twenty-one patients. Refracture occurred in twelve patients; five fractures healed with closed treatment, five healed after an additional surgical procedure, and two ultimately required amputation. Ten patients had an ankle valgus deformity after tibial union. Eleven patients had a residual limb-length discrepancy of >2 cm; six required a contralateral distal femoral and/or proximal tibial epiphyseodesis, two had a tibial lengthening, and one used a shoe-lift. Five patients had an amputation: two, because of a recalcitrant fracture; two, because of a limb-length discrepancy (6 and 9 cm); and one, because of a chronic lower-extremity deformity.
CONCLUSIONS: This technique produced a satisfactory long-term functional outcome in sixteen of twenty-one patients and should be considered for the management of congenital pseudarthrosis of the tibia.

Entities:  

Mesh:

Year:  2005        PMID: 15743845     DOI: 10.2106/JBJS.D.02764

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  7 in total

1.  Periosteal grafting for congenital pseudarthrosis of the tibia: a preliminary report.

Authors:  Ahmed M Thabet; Dror Paley; Mehmet Kocaoglu; Levent Eralp; John E Herzenberg; Omer Naci Ergin
Journal:  Clin Orthop Relat Res       Date:  2008-10-25       Impact factor: 4.176

2.  Vascularised fibular graft for the treatment of congenital pseudarthrosis of the tibia: long-term complications in the donor leg.

Authors:  Raquel B Iamaguchi; Patricia M M B Fucs; Antonio Carlos da Costa; Ivan Chakkour
Journal:  Int Orthop       Date:  2010-08-01       Impact factor: 3.075

3.  Masquelet's procedure and bone morphogenetic protein in congenital pseudarthrosis of the tibia in children: a case series and meta-analysis.

Authors:  Bruno Dohin; Remi Kohler
Journal:  J Child Orthop       Date:  2012-07-21       Impact factor: 1.548

4.  The use of recombinant morphogenic protein-2(rhBMP-2) in children undergoing revision surgery for persistent non-union.

Authors:  Madhavan C Papanna; K A Saldanha; Binu Kurian; James A Fernandes; Stan Jones
Journal:  Strategies Trauma Limb Reconstr       Date:  2016-03-16

5.  The association between fibular status and frontal plane tibial alignment post-union in congenital pseudarthrosis of the tibia.

Authors:  Huajun Deng; Haibo Mei; Enbo Wang; Qiwei Li; Lijun Zhang; Federico Canavese; Lianyong Li
Journal:  J Child Orthop       Date:  2021-06-01       Impact factor: 1.548

6.  Congenital pseudarthrosis of the tibia treated with a combination of Ilizarov's technique and intramedullary rodding.

Authors:  Mandar Vikas Agashe; Sang-Heon Song; Mohammad Ahmed Refai; Kwang-Won Park; Hae-Ryong Song
Journal:  Acta Orthop       Date:  2012-10-08       Impact factor: 3.717

7.  Management of spinal deformities and tibial pseudarthrosis in children with neurofibromatosis type 1 (NF-1).

Authors:  Kiril V Mladenov; Alexander Simon Spiro; Kara Leigh Krajewski; Ralf Stücker; Philip Kunkel
Journal:  Childs Nerv Syst       Date:  2020-07-01       Impact factor: 1.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.